AMANDA MARTIN: Open Payments
NPI 1356538045 · TUPELO, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,781 in 88 payments from 15 companies in 2025. Trend: 2023 $629 · 2024 $832 · 2025 $1,781
Food & beverage: $1,781
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $398 |
| ABBVIE INC. | 25 | $241 |
| Axsome Therapeutics, Inc. | 7 | $173 |
| Janssen Pharmaceuticals, Inc | 7 | $169 |
| Vanda Pharmaceuticals Inc. | 10 | $136 |
| Novo Nordisk Inc | 2 | $126 |
| Supernus Pharmaceuticals, Inc. | 4 | $107 |
| Phathom Pharmaceuticals, Inc. | 1 | $105 |
| Otsuka America Pharmaceutical, Inc. | 5 | $100 |
| Collegium Pharmaceutical, Inc. | 4 | $75 |
Products named: CAPLYTA, VRAYLAR, Auvelity, INVEGA SUSTENNA, FANAPT, REXULTI, Qelbree, VOQUEZNA.
Industry payments across MS — which companies pay providers there.
